| Year |
Citation |
Score |
| 2024 |
Nacev BA, Dabas Y, Paul MR, Pacheco C, Mitchener M, Perez Y, Fang Y, Soshnev AA, Barrows D, Carroll T, Socci ND, St Jean SC, Tiwari S, Gruss MJ, Monette S, et al. Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation. Nature Communications. 15: 5155. PMID 38886411 DOI: 10.1038/s41467-024-49486-5 |
0.719 |
|
| 2021 |
Bagert JD, Mitchener MM, Patriotis AL, Dul BE, Wojcik F, Nacev BA, Feng L, Allis CD, Muir TW. Oncohistone mutations enhance chromatin remodeling and alter cell fates. Nature Chemical Biology. PMID 33649601 DOI: 10.1038/s41589-021-00738-1 |
0.49 |
|
| 2020 |
Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, Ladanyi M, Nielsen TO. The epigenomics of sarcoma. Nature Reviews. Cancer. PMID 32782366 DOI: 10.1038/S41568-020-0288-4 |
0.514 |
|
| 2019 |
Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, Kundra R, Schultz N, Muir TW, Allis CD. The expanding landscape of 'oncohistone' mutations in human cancers. Nature. PMID 30894748 DOI: 10.1038/S41586-019-1038-1 |
0.716 |
|
| 2018 |
Nacev BA, Tap WD. TOMAS: revisiting PARP inhibitor combination therapy. The Lancet. Oncology. PMID 30217674 DOI: 10.1016/S1470-2045(18)30494-7 |
0.316 |
|
| 2017 |
Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, Li RJ, Shim JS, Liu JO. Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. Acs Chemical Biology. 12: 174-182. PMID 28103683 DOI: 10.1021/Acschembio.6B00849 |
0.652 |
|
| 2015 |
Kshitiz, Afzal J, Suhail Y, Ahn EH, Goyal R, Hubbi ME, Hussaini Q, Ellison DD, Goyal J, Nacev B, Kim DH, Lee JH, Frankel S, Gray K, Bankoti R, et al. Control of the interface between heterotypic cell populations reveals the mechanism of intercellular transfer of signaling proteins. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 364-72. PMID 25784457 DOI: 10.1039/C4Ib00209A |
0.358 |
|
| 2015 |
Pandey R, Botros MA, Nacev BA, Albig AR. Cyclosporin a disrupts notch signaling and vascular lumen maintenance. Plos One. 10: e0119279. PMID 25775018 DOI: 10.1371/Journal.Pone.0119279 |
0.425 |
|
| 2015 |
Chi P, Qin L, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev B, Crago AM, Yoon SS, Ulaner GA, Martindale M, Condy MM, Phelan H, et al. A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 33: 10507-10507. DOI: 10.1200/Jco.2020.38.15_Suppl.11508 |
0.359 |
|
| 2013 |
Zhang F, Bhat S, Gabelli SB, Chen X, Miller MS, Nacev BA, Cheng YL, Meyers DJ, Tenney K, Shim JS, Crews P, Amzel LM, Ma D, Liu JO. Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells Journal of Medicinal Chemistry. 56: 3996-4016. PMID 23634668 DOI: 10.1021/Jm400227Z |
0.742 |
|
| 2012 |
Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO. Abstract 2316: Itraconazole, an antifungal drug with anti-angiogenic activity, inhibits VEGFR2 trafficking, glycosylation, and signaling in endothelial cells Cancer Research. 72: 2316-2316. DOI: 10.1158/1538-7445.Am2012-2316 |
0.565 |
|
| 2011 |
Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. The Journal of Biological Chemistry. 286: 44045-56. PMID 22025615 DOI: 10.1074/Jbc.M111.278754 |
0.552 |
|
| 2011 |
Nacev BA, Liu JO. Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole. Plos One. 6: e24793. PMID 21969860 DOI: 10.1371/Journal.Pone.0024793 |
0.526 |
|
| 2011 |
Shi W, Nacev BA, Aftab BT, Head S, Rudin CM, Liu JO. Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. Journal of Medicinal Chemistry. 54: 7363-74. PMID 21936514 DOI: 10.1021/Jm200944B |
0.773 |
|
| 2011 |
Nacev BA, Low WK, Huang Z, Su TT, Su Z, Alkuraya H, Kasuga D, Sun W, Träger M, Braun M, Fischer G, Zhang K, Liu JO. A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog. The Journal of Pharmacology and Experimental Therapeutics. 338: 466-75. PMID 21562139 DOI: 10.1124/Jpet.111.180851 |
0.79 |
|
| 2011 |
Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, Isaacs WB. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). Molecular Cancer Therapeutics. 10: 825-38. PMID 21441411 DOI: 10.1158/1535-7163.Mct-10-0902 |
0.437 |
|
| 2011 |
Aftab BT, Shi W, Nacev BA, Head S, Liu JO, Rudin CM. Abstract C147: Itraconazole side-chain analogs reveal a distinct structure-activity relationship for inhibition of hedgehog pathway signaling. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C147 |
0.78 |
|
| 2010 |
Shi W, Nacev BA, Bhat S, Liu JO. Impact of Absolute Stereochemistry on the Antiangiogenic and Antifungal Activities of Itraconazole. Acs Medicinal Chemistry Letters. 1: 155-159. PMID 21892383 DOI: 10.1021/Ml1000068 |
0.709 |
|
| 2010 |
Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. Journal of the National Cancer Institute. 102: 1855-73. PMID 21088277 DOI: 10.1093/Jnci/Djq457 |
0.742 |
|
| 2010 |
Xiao Q, Zhang F, Nacev BA, Liu JO, Pei D. Protein N-terminal processing: substrate specificity of Escherichia coli and human methionine aminopeptidases. Biochemistry. 49: 5588-99. PMID 20521764 DOI: 10.1021/Bi1005464 |
0.605 |
|
| 2009 |
Liu JO, Nacev BA, Xu J, Bhat S. It takes two binding sites for calcineurin and NFAT to tango. Molecular Cell. 33: 676-8. PMID 19328062 DOI: 10.1016/J.Molcel.2009.03.005 |
0.659 |
|
| Show low-probability matches. |